ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber

Septic Shock Clinical Trial

— ASSET  

Official title:

Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02335723
• Other study ID #: ALT-CI-01
• Status: Terminated
• Phase: N/A
• First received: November 28, 2014
• Last updated: March 6, 2018
• Start date: September 2015
• Est. completion date: April 28, 2017

Study information

• Verified date: March 2018
• Source: Alteco Medical AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this clinical investigation is to investigate the feasibility and possible benefits of the Alteco® LPS Adsorber in treating patients with septic shock with presumed endotoxemia of abdominal or urogenital origin.

Description:

OVERALL CLINICAL INVESTIGATION DESIGN:

This is a multicentre, stratified, parallel, double-blinded, randomized, feasibility clinical investigation of the Alteco® LPS Adsorber.

Subjects will be enrolled in an adaptive fashion with up to two interim analyses, and the possibility of recruiting additional patients, in order to establish an indication of the feasibility of treating a target population of subjects with septic shock and endotoxemia.

Subjects will be stratified in accordance with the origin of their infection, i.e. abdominal or urogenital sepsis. Subjects in each stratum will receive either:

• LPS Adsorber group (i.e. investigational medical device [IMD] group): current best practice in combination with Alteco® LPS Adsorber treatment, OR

• Placebo device group (i.e. comparator group): current best practice in combination with placebo adsorber treatment.

Allocation to either treatment arm will be performed in a 1:1 ratio. Upon enrolment (i.e. pre-treatment phase), subjects admitted to the ICU with suspected endotoxemia will be screened for fulfilment of the "Illness Severity Criteria" confirming early stage severe sepsis.

Within six (6) hours of enrolment, subjects who also fulfil the "Treatment Criteria" confirming septic shock will be eligible for randomization.

Randomization to either of the treatment groups will be performed as close as possible to start of treatment with the Alteco® LPS Adsorber or placebo device.

Treatment with LPS Adsorber or placebo device must be initiated within six (6) hours (Day 1) following fulfilment of the "Treatment Criteria". A second device treatment will be performed 24 hours after the end of the first device treatment on Day 2, as long there is no evidence that treatment with the investigational device will not be beneficial or will indicate an unnecessary risk for subjects (for example, the subject is vasopressor support-free).

Initially: 20 abdominal sepsis subjects (Stratum A) and 12 urogenital sepsis subjects (Stratum B) Optional: additional 12 subjects (abdominal, urogenital or both) after interim analysis decision.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: April 28, 2017
• Est. primary completion date: April 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Illness severity criteria: At enrolment subjects must meet inclusion criteria #1 through #3 listed below to be eligible to enter the clinical investigation:

1. Subjects must have suspected severe infection of abdominal or urogenital origin for which the subject is receiving intravenous antimicrobial therapy as the main reason for organ support

2. Subjects, males or females, must be 18 years or older.

3. Subjects or legally acceptable representatives, as appropriate, are willing and able to provide signed informed consent.

Treatment criteria: Prior to randomization, subjects must meet all inclusion criteria (#4 through #7) listed below to be assigned to a treatment group:

4. Appropriate vascular access must have been obtained.

5. Subjects must have received = 30 mL/kg of intravenous fluid within the six (6) hours prior to randomization.

6. Subjects must have plasma/serum lactate >2 mmol/L despite adequate resuscitation AND a continuous requirement for vasopressor support

7. Subjects must be able to initiate the clinical investigation intervention within 12 hours of fulfilment of the illness severity criteria.

Exclusion Criteria:

1. Subjects who meet any of the exclusion criteria listed below will NOT be permitted to enter the clinical investigation: Sepsis-induced organ dysfunction for longer than 12 hours prior to the time-point for achieving "Illness severity criteria fulfilled"

2. Vasopressor therapy (at any dose) for longer than 12 hours (not included the time spent in the operation theatre) prior to the start of treatment with the investigational device.

3. Pre-existing uncorrectable medical condition as:

• Poorly controlled neoplasms or hematologic disease (i.e. indication of disseminated cancer outside the suspected primary tumour and hematologic disease not in remission,

• End-stage cardiac disease,

• Cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within the past 7 days

• End-stage lung disease

• End-stage liver disease

• HIV/AIDS with known end-stage processes

• Other uncorrectable medical condition(s) deemed by the Clinical Investigator to hinder the subject to adhere to the fulfilment of the activities described in the Clinical Investigation Plan.

4. Extreme illness, i.e. subjects is moribund and death is perceived to be imminent (within 24 hours).

5. Recent or current participation (= 30 days) in another interventional sepsis trial.

6. Recent or current treatment (= 30 days) with an adsorption product, including Alteco® LPS Adsorber.

7. Treatment with an investigational medicinal product for any indication within the last 30 days before enrolment in the clinical investigation.

8. Pregnancy.

9. Contraindications to the use heparin or protamine

10. Other abdominal inflammatory conditions

11. Perforation of hollow organ linked to trauma within 48 hours before enrolment in the clinical investigation.

12. Laparotomy reveals isolated gastric ulcer.

13. Subjects and/or their immediate family are directly affiliated to investigative site personnel in this clinical investigation. (Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted).

Related Conditions & MeSH terms

• Septic Shock
• Shock, Septic

Intervention

Device:
• Alteco LPS Adsorber
Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components. Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species.
• Placebo
Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)

Locations

Country	Name	City	State
Finland	Kuopio University Hospital	Kuopio
Finland	Tampere University Hospital	Tampere
Norway	Haukeland Universitetssykehus	Bergen
Norway	Oslo Universitetssykehus	Oslo
Sweden	Linköping University Hospital	Linköping
Sweden	Uppsala University Hospital	Uppsala

Sponsors (3)

Lead Sponsor	Collaborator
Alteco Medical AB	TFS Trial Form Support, Uppsala University

Countries where clinical trial is conducted

Finland,  Norway,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterization of all reported USADEs and ASADEs.		6-28 days
Secondary	Relative change from baseline in plasma endotoxin (p-endotoxin) levels during (i.e. at 2 hours) and immediately after end (i.e. at 6 hours) of treatment with device, on both Day 1 and Day 2.		2 days
Secondary	Relative change from baseline in SOFA score		6-28 days
Secondary	Relative change from baseline in renal function	Renal function is assessed by: S-creatinine, P-Cystatin C, P-Urea, eGFR, KDIGO stage, Fluid balance, and Daily urinary output	6-28 days
Secondary	Relative change from baseline in liver function	Liver function is assessed by: Prothrombin complex INR, P-Albumin, and P-Bilirubin	6-28 days
Secondary	Relative change from baseline in circulatory support	Circulatory support is assessed by: Vasopressor load, Inotropic score, MAP, Vasopressor dependence index, P-Lactate, Blood gas, and Vasopressor-free days.	6-28 days
Secondary	Relative change from baseline in respiratory support	Respiratory support is assessed by: PaO2, FiO2 and PaO2/FiO2 ratio, Positive and expiratory pressure, Peak pressure, Tidal volume and minute volume, Respiratory rate, Pa CO2, Respiratory support need as measured by means of ventilator-free days until day for ICU discharge	6-28 days
Secondary	Relative change from baseline in ICU mortality		6-28 days
Secondary	Relative change from baseline in ICU length of stay		6-28 days
Secondary	Clinical outcome during stay at Hospital following ICU-discharge of the total extension of renal support		6-28 days
Secondary	Clinical outcome during stay at Hospital following ICU-discharge of 28-day mortality		6-28 days
Secondary	Clinical outcome during stay at Hospital following ICU-discharge of hospital length of stay up to 28 days		6-28 days
Secondary	Levels of inflammatory response biomarkers		6-28 days
Secondary	Determination of the molecular components extracted from blood circulation and captured in Alteco® LPS Adsorber.	This is an exploratory outcome, there will be a screening of which molecules that have been captured.	6-28 days
Secondary	Characterization of all reported AEs (regardless of attribution), ADEs, and device deficiencies		6-28 days